News

H. pylori test OK for people on PPIs, with caution


 

The Helicobacter pylori breath test can now be used in patients who have taken proton pump inhibitors within the previous 2 weeks, according to the manufacturer, Otsuka America Pharmaceutical Inc.

In a June 4 statement, the company said that the labeling of the BreathTek UBT for H. pylori kit has been updated to include this information, which is based on studies that evaluated the effects of PPI use in people taking the test. However, in this scenario, "the test result needs to be interpreted with caution," and the recommendation that patients not take antimicrobials, PPIs, and bismuth preparations within 2 weeks of the test still stands, the statement adds.

The label change makes it possible to test patients on a PPI for an initial diagnosis of H. pylori infection without stopping the PPI, providing "an opportunity of earlier detection and start of eradication therapy for H. pylori infection," according to Otsuka. Ingestion of PPIs within 2 weeks of the test can cause a false negative result, and the test should be repeated 2 weeks after the PPI therapy is stopped, if a patient has a negative test while taking a PPI, according to the warnings and precautions for the product.

Ingestion of bismuth preparations or antimicrobials can also cause a false negative result, if taken within 2 weeks of the test.

emechcatie@frontlinemedcom.com

Recommended Reading

Guidelines accurately predict risk of common bile duct stones
MDedge Internal Medicine
Cohort study shows link between colonoscopy, overall mortality
MDedge Internal Medicine
Bariatric surgery less efficacious in blacks
MDedge Internal Medicine
Nosocomial infection in cirrhotic patients boosts acute kidney injury risk
MDedge Internal Medicine
EET and esophagectomy yield similar cancer-free survival
MDedge Internal Medicine
Mesalamine a bust at diverticulitis prevention
MDedge Internal Medicine
Benefits of laparoscopic over open colectomy decrease with operative time
MDedge Internal Medicine
Telaprevir-based triple-drug therapy benefits CHC patients with ESRD
MDedge Internal Medicine
TLR9 agonist active against ulcerative colitis in small study
MDedge Internal Medicine
Chemoimmunotherapy, chemoradiotherapy add no survival in pancreatic cancer
MDedge Internal Medicine